


PHARMACEUTICAL 2018



Enveric Biosciences Inc. Rank 206 of 342





PHARMACEUTICAL 2018



Enveric Biosciences Inc. Rank 206 of 342

The relative strengths and weaknesses of Enveric Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enveric Biosciences Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 100% points. The greatest weakness of Enveric Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is 55%, being 9.4% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	14,645
Cost of Goods Sold	38,356
Intangible Assets	31,368
Liabilities, Current	30,368
Liabilities, Non-Current	2,381
Other Assets	6,089
Other Compr. Net Income	-2,045
Other Expenses	1,307
Other Liabilities	0
Other Net Income	504
Other Revenues	48,594
Property and Equipment	95
Research and Development	0
Selling, General and Administrative Expense	18,510

Output Variable	Value in 1000 USD
Assets	52,197
Liabilities	32,748
Expenses	58,173
Revenues	48,594
Stockholders Equity	19,448
Net Income	-9,075
Comprehensive Net Income	-10,097
Economic Capital Ratio	55%

